Results 231 to 240 of about 4,854,757 (315)

From In‐Silico Optimized Microfabrication to Experimental Validation: Engineering a Tridimensional Epi‐Intraneural Interface

Advanced Functional Materials, EarlyView.
An epi‐intraneural interface is developed through in silico optimization and a novel tridimensional microfabrication pipeline. The device integrates penetrating and epineural contacts on a flexible substrate. Mechanical, electrochemical, and in vivo testing in rat and pig reveal robust implantation, low‐threshold activation, and site‐dependent ...
Federico Ciotti, Andrea Cimolato, Noemi Gozzi, Pietro Palopoli, Luca Brugnoli, Natalija Katic Secerovic, Rebecca Gallivan, Alexander Shokurov, Carlo Menon, Johannes Weichart, Ignacio Delgado‐Martinez, Weiguo Song, Stavros Zanos, Xavier Navarro, Stanisa Raspopovic   +14 more
wiley   +1 more source

Liquid Crystalline Inverted Lipid Phases and Reverse Micelles in Drug Delivery: From Molecular Design to Therapeutic Potential

Advanced Functional Materials, EarlyView.
Liquid crystalline inverted lipid phases and reverse micelles are self‐assembled lipid nanostructures that enhance the solubility, stability, and delivery of diverse therapeutics. This review integrates their physicochemical principles, formulation strategies, drug loading mechanisms, and biomedical applications, highlighting their growing ...
Numan Eczacioglu, Mulazim Hussain Asim, Soheil Haddadzadegan, Andreas Bernkop‐Schnürch   +3 more
wiley   +1 more source

Laser‐Microscribed Glass Enables Surface‐Microfluidics‐Facilitated, Affordable, Rapid Cancer Diagnosis

Advanced Functional Materials, EarlyView.
A transparent, laser‐microscribed glass platform enables cancer diagnosis within 1 h—much faster than histology, which takes days, and free from the chemical or contrast risks of MRI or CT scans. The antibody‐functionalized rough glass surface captures viable cancer cells directly from suspension, allowing instant optical readout and offering a rapid ...
Anish Pal, Snehasis Mishra, Arani Mukhopadhyay, Ilias Papailias, Atique U. Ahmed, Constantine M. Megaridis   +5 more
wiley   +1 more source

Navigating Postacute Care Pathways Following Hospital Discharge in Plastic Surgery. [PDF]

Plast Reconstr Surg Glob Open
Quach MP, Zona EE, Craig JN, Seitz AJ, Rao VK.   +4 more
europepmc   +1 more source

Predictors of Home Discharge Among Patients Hospitalized for Acute Respiratory Diseases. [PDF]

Cureus
Yamazaki T, Tsuchiya M, Nagasaka Y, Kotani S, Iwai K, Anami K, Horie J.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

ECMO as a Destination Therapy is Not a Bridge to Nowhere

American Journal of Bioethics, 2023
Among the terms that has become a stock phrase in articles about ECMO, whether academic or news stories, is “bridge to nowhere” (Abrams et.al. 2014; Bailey 2019).
W. Allen
semanticscholar   +1 more source

Devices as destination therapy

Cardiology Clinics, 2003
The use of circulatory support as destination therapy has been a goal for the treatment of endstage heart failure for several decades. Current investigations are evaluating several circulatory pumps with that particular objective. With continued modification of design, the current and future pumps will become more reliable and provide improved quality ...
Eugene L, Kukuy, Mehmet C, Oz, Eric A, Rose, Yoshifumi, Naka   +3 more
openaire   +2 more sources

Device Thrombosis During Destination Therapy

The American Journal of the Medical Sciences, 2016
Device thrombosis remains a complication of long-term mechanical circulatory support with HeartMate II.Retrospective analysis of patients who underwent destination therapy (DT) with HeartMate II from January 2010-December 2013 at Tulane University Medical Center.Eighteen HeartMate II were implanted for DT. Survival rates were 72.2% at 1 year and 37% at
Rohan, Samson, Indranee, Rajapreyar, Abhishek, Jaiswal, Brian, Payne, Mark, Cassidy, Michael, Weaver, Thierry H, Le Jemtel   +6 more
openaire   +2 more sources

Total artificial heart: Destination therapy

Cardiology Clinics, 2003
The AbioCor is a revolutionary device. It is the only device of its kind in the clinical world. The role of the AbioCor is to provide permanent replacement of the failing heart for patients who are not transplant candidates. The clinical trial has been successful in the majority (four of seven) of patients implanted thus far.
Louis E, Samuels, Robert, Dowling
openaire   +2 more sources